Based on what's been presented, would suggest is that Demand...

Based on what's been presented, would suggest is that Demand would be wholesale data. Like prescriptions from pharmacy and doctors.

I'm not going to pull the original Mithra agreement - but is the commission aspect a licencing fee or based on sales like TmdD? Again - reading the charts, perhaps Mithra is a licencing agreement and therefore $ are paid on production. Would support Demand = Mithra #'s.

IQVIA is retail data (converted sales/dispensed units) and probably the more reliable as this translates to revenue. I have to confess; until *MYX switched* - I would have assumed one and the same.

As for under-representing - I can't for the life of me see a reason for MYX to do this. The last three years the market has reacted aggressively to *all* mentions of Nextstellis, so any underrepresentation would have expected a market reaction.

It has been savage with little support - very surprising... I wonder if they've lost a Top 20 holder - perhaps the next few days will explain better.